Tvardi Therapeutics, Inc. Common Stock (TVRD)

• Market cap: $159M
• 1 day: 0.00%
• 5 days: -5.12%
• 1 month: 0.00%
• 3 months: 0.00%
• 6 months: 0.00%
• Year to date: 0.00%
• 1 year: 0.00%
• 5 years: 0.00%
• 10 years: 0.00%

About: Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.